Paxlovid (Nirmatrelvir) Manufacturing Enzyme
COVID-19
CommercialCompleted Supply
Key Facts
About Codexis
Founded in 2002, Codexis has pioneered the use of engineered enzymes for pharmaceutical manufacturing, with a proven track record including the scale-up of an enzyme for Pfizer's Paxlovid. The company has strategically expanded into RNA manufacturing, offering a full enzymatic synthesis platform for oligonucleotides like siRNA. Codexis operates as a partner-driven business, providing custom enzyme solutions and manufacturing services to accelerate and de-risk therapeutic development for its clients.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| Remdesivir (Veklury) | Gilead Sciences | Approved |
| mRNA-1273 (Spikevax) | Moderna | Approved |
| Investigational Oral COVID-19 Antiviral | Shionogi | Clinical |
| ZyCoV-D | Zydus Lifesciences | Approved |
| BBIBP-CorV | Sinopharm | Approved |
| SARS-CoV-2 Neutralizing Antibodies | Adaptive Biotechnologies | Discovery |
| Covovax™ | Novavax | Approved/Commercial |
| LY-CoV555 (Bamlanivimab) | AbCellera | Emergency Use Authorization (Past) |
| ARCT-154 (Bivalent) | Arcturus Therapeutics | Phase 1/2 |
| LUNAR-COV19 (ARCT-021) | Arcturus Therapeutics | Phase 1/2 |